

ASX Code: GSS
22 October 2018

Appointment of Chief Financial Officer

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”) is pleased to announce the appointment of Peter Manley, a highly qualified global life sciences industry executive, as Chief Financial Officer. Peter will join the Company on 22 October 2018.

Genetic Signatures CEO, Dr. John Melki commented:

“Peter brings a wealth of senior financial leadership experience to Genetic Signatures and we are excited about the value he will bring to the Company. We are pleased to have Peter joining us at an important inflection point, ready to support the Company as we continue to accelerate sales in both domestic and key international markets. Peter will play a key role in allowing the Company to deliver sustainable growth and pursue growth opportunities.”

Peter has extensive experience as a finance professional in the life sciences industry having served as CFO and company secretary for both AtCor Medical Holdings Limited (now Cardix) and Sirtex Medical Ltd. Prior to this, he held financial positions in a variety of large Australian and foreign-owned corporations, including 8 years with Dow Chemical and 4 years with Goodman Fielder, Australia’s largest food company. He is both a CPA and a member of the Governance Institute of Australia.

Peter’s appointment follows Genetic Signature’s recent European and domestic registration of the *EasyScreen™* ESBL & CPO ‘Superbug’ Detection Kit and comes as the Company is actively preparing to secure further regulatory approvals and expand the number of *EasyScreen™* Detection Kits available for sale in Australia, Europe and the US.

Peter will replace Mark Langan who was retained by the Company in August 2015 and has supported Genetic Signatures since listing on the Australian Securities Exchange. Mr. Langan will continue to be retained by the Company to fulfill its growth opportunities.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki
Chief Executive Officer
john@geneticsignatures.com
T: +61 (0)2 9870 7580

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its

proprietary platform technology, **3base**[™]. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*[™] brand. Genetic Signatures' proprietary MDx **3base**[™] platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.